{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:33:55Z","timestamp":1791999235819,"version":"4.4.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tumor growth is intricately linked to the process of angiogenesis, with a key role played by vascular endothelial growth factor (VEGF) and its associated signaling pathways. Notably, these pathways also play a pivotal \u201chousekeeping\u201d role in renal physiology. Over the past decade, the utilization of VEGF signaling inhibitors has seen a substantial rise in the treatment of diverse solid organ tumors, diabetic retinopathy, age-related macular degeneration, and various ocular diseases. However, this increased use of such agents has led to a higher frequency of encountering renal adverse effects in clinical practice. This review comprehensively addresses the incidence, pathophysiological mechanisms, and current evidence concerning renal adverse events associated with systemic and intravitreal antiangiogenic therapies targeting VEGF-A and its receptors (VEGFR) and their associated signaling pathways. Additionally, we briefly explore strategies for mitigating potential risks linked to the use of these agents and effectively managing various renal adverse events, including but not limited to hypertension, proteinuria, renal dysfunction, and electrolyte imbalances.<\/jats:p>","DOI":"10.1007\/s11255-024-03990-1","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T15:02:26Z","timestamp":1710774146000},"page":"2635-2644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ocular and systemic vascular endothelial growth factor ligand inhibitor use and nephrotoxicity: an update"],"prefix":"10.1007","volume":"56","author":[{"given":"Dharshan","family":"Rangaswamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar Prasad","family":"Nagaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan Varadanayakanahalli","family":"Bhojaraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilna Muttickal","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra A.","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indu Ramachandra","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7405-4106","authenticated-orcid":false,"given":"Srinivas Vinayak","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"3990_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/17512433.2020.1734450","volume":"13","author":"W Zhang","year":"2020","unstructured":"Zhang W, Feng L-J, Teng F, Li Y-H, Zhang X, Ran Y-G (2020) Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials. Expert Rev Clin Pharmacol 13:311\u2013320","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3990_CR2","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.3390\/ijms17122073","volume":"17","author":"A Semeniuk-Wojta\u015b","year":"2016","unstructured":"Semeniuk-Wojta\u015b A, Lubas A, Stec R, Szczylik C, Niemczyk S (2016) Influence of tyrosine kinase inhibitors on hypertension and nephrotoxicity in metastatic renal cell cancer patients. Int J Mol Sci 17:2073","journal-title":"Int J Mol Sci"},{"key":"3990_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11523-015-0368-7","volume":"10","author":"A Abbas","year":"2015","unstructured":"Abbas A, Mirza MM, Ganti AK, Tendulkar K (2015) Renal toxicities of targeted therapies. Target Oncol 10:487\u2013499","journal-title":"Target Oncol"},{"key":"3990_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4062\/biomolther.2013.113","volume":"22","author":"M Shibuya","year":"2014","unstructured":"Shibuya M (2014) VEGF-VEGFR signals in health and disease. Biomol Ther (Seoul) 22:1\u20139","journal-title":"Biomol Ther (Seoul)"},{"key":"3990_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ki.2013.344","volume":"85","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Mangier M, Ory V, Zhang S-Y, Sendeyo K, Bouachi K et al (2014) Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int 85:457\u2013470","journal-title":"Kidney Int"},{"key":"3990_CR6","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1038\/s41467-019-09936-x","volume":"10","author":"RC Calizo","year":"2019","unstructured":"Calizo RC, Bhattacharya S, van Hasselt JGC, Wei C, Wong JS, Wiener RJ et al (2019) Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity. Nat Commun 10:2061","journal-title":"Nat Commun"},{"key":"3990_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","volume":"27","author":"JS Penn","year":"2008","unstructured":"Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME (2008) Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 27:331\u2013371","journal-title":"Prog Retin Eye Res"},{"key":"3990_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.sjopt.2018.05.002","volume":"32","author":"AS Al-Kharashi","year":"2018","unstructured":"Al-Kharashi AS (2018) Role of oxidative stress, inflammation, hypoxia and angiogenesis in the development of diabetic retinopathy. Saudi J Ophthalmol 32:318\u2013323","journal-title":"Saudi J Ophthalmol"},{"key":"3990_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40942-019-0179-6","volume":"5","author":"S Ahuja","year":"2019","unstructured":"Ahuja S, Saxena S, Akduman L, Meyer CH, Kruzliak P, Khanna VK (2019) Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy. Int J Retina Vitreous 5:29","journal-title":"Int J Retina Vitreous"},{"key":"3990_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2011.10.001","volume":"87","author":"MW Stewart","year":"2012","unstructured":"Stewart MW (2012) The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc 87:77\u201388","journal-title":"Mayo Clin Proc"},{"key":"3990_CR11","first-page":"235","volume":"59","author":"S Cornel","year":"2015","unstructured":"Cornel S, Adriana ID, Mihaela TC, Speranta S, Algerino DS, Mehdi B et al (2015) Anti-vascular endothelial growth factor indications in ocular disease. Rom J Ophthalmol 59:235\u2013242","journal-title":"Rom J Ophthalmol"},{"key":"3990_CR12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.kint.2019.02.042","volume":"96","author":"RM Hanna","year":"2019","unstructured":"Hanna RM, Barsoum M, Arman F, Selamet U, Hasnain H, Kurtz I (2019) Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int 96:572\u2013580","journal-title":"Kidney Int"},{"key":"3990_CR13","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1093\/ckj\/sfab066","volume":"14","author":"G Phadke","year":"2021","unstructured":"Phadke G, Hanna RM, Ferrey A, Torres EA, Singla A, Kaushal A et al (2021) Review of intravitreal VEGF inhibitor toxicity and report of collapsing FSGS with TMA in a patient with age-related macular degeneration. Clin Kidney J 14:2158\u20132165","journal-title":"Clin Kidney J"},{"key":"3990_CR14","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/ckj\/sfaa049","volume":"13","author":"M Shye","year":"2020","unstructured":"Shye M, Hanna RM, Patel SS, Tram-Tran N, Hou J, Mccannel C et al (2020) Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy. Clin Kidney J 13:969\u2013980","journal-title":"Clin Kidney J"},{"key":"3990_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MNH.0000000000000760","volume":"31","author":"RM Hanna","year":"2022","unstructured":"Hanna RM, Ahdoot RS, Kim MS, Jhaveri KD, Kalantar-Zadeh K, Kurtz IB (2022) Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review. Curr Opin Nephrol Hypertens 31:47\u201356","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"3990_CR16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/ckj\/sfy060","volume":"12","author":"RM Hanna","year":"2019","unstructured":"Hanna RM, Lopez EA, Hasnain H, Selamet U, Wilson J, Youssef PN et al (2019) Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clin Kidney J 12:92\u2013100","journal-title":"Clin Kidney J"},{"key":"3990_CR17","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","volume":"65","author":"BF Schrijvers","year":"2004","unstructured":"Schrijvers BF, Flyvbjerg A, De Vriese AS (2004) The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65:2003\u20132017","journal-title":"Kidney Int"},{"key":"3990_CR18","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/ndt\/gfu368","volume":"30","author":"M Ollero","year":"2015","unstructured":"Ollero M, Sahali D (2015) Inhibition of the VEGF signalling pathway and glomerular disorders. Nephrol Dial Transplant 30:1449\u20131455","journal-title":"Nephrol Dial Transplant"},{"key":"3990_CR19","doi-asserted-by":"publisher","first-page":"F747","DOI":"10.1152\/ajprenal.00617.2017","volume":"315","author":"E Guise","year":"2018","unstructured":"Guise E, Chade AR (2018) VEGF therapy for the kidney: emerging strategies. Am J Physiol-Renal Physiol 315:F747\u2013F751","journal-title":"Am J Physiol-Renal Physiol"},{"key":"3990_CR20","doi-asserted-by":"publisher","first-page":"p32","DOI":"10.1159\/000101798","volume":"106","author":"V Eremina","year":"2007","unstructured":"Eremina V, Baelde HJ, Quaggin SE (2007) Role of the VEGF\u2013a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 106:p32\u2013p37","journal-title":"Nephron Physiol"},{"key":"3990_CR21","doi-asserted-by":"publisher","first-page":"F1656","DOI":"10.1152\/ajprenal.00275.2009","volume":"297","author":"J M\u00fcller-Deile","year":"2009","unstructured":"M\u00fcller-Deile J, Worthmann K, Saleem M, Tossidou I, Haller H, Schiffer M (2009) The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am J Physiol Renal Physiol 297:F1656\u2013F1667","journal-title":"Am J Physiol Renal Physiol"},{"key":"3990_CR22","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.2337\/DB11-1655","volume":"61","author":"GA Sivaskandarajah","year":"2012","unstructured":"Sivaskandarajah GA, Jeansson M, Maezawa Y, Eremina V, Baelde HJ, Quaggin SE (2012) Vegfa protects the glomerular microvasculature in diabetes. Diabetes 61:2958\u20132966","journal-title":"Diabetes"},{"key":"3990_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41581-020-0260-2","volume":"16","author":"K Tanabe","year":"2020","unstructured":"Tanabe K, Wada J, Sato Y (2020) Targeting angiogenesis and lymphangiogenesis in kidney disease. Nat Rev Nephrol 16:289\u2013303","journal-title":"Nat Rev Nephrol"},{"key":"3990_CR24","doi-asserted-by":"publisher","first-page":"F1648","DOI":"10.1152\/ajprenal.00099.2008","volume":"295","author":"EC Leonard","year":"2008","unstructured":"Leonard EC, Friedrich JL, Basile DP (2008) VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury. Am J Physiol Renal Physiol 295:F1648\u2013F1657","journal-title":"Am J Physiol Renal Physiol"},{"key":"3990_CR25","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1681\/ASN.V1271448","volume":"12","author":"D-H Kang","year":"2001","unstructured":"Kang D-H, Hughes J, Mazzali M, Schreiner GF, Johnson RJ (2001) Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 12:1448\u20131457","journal-title":"J Am Soc Nephrol"},{"key":"3990_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1681\/ASN.2015050491","volume":"27","author":"AR Chade","year":"2016","unstructured":"Chade AR (2016) Vascular endothelial growth factor therapy for the kidney: are we there yet? J Am Soc Nephrol 27:1\u20133","journal-title":"J Am Soc Nephrol"},{"key":"3990_CR27","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/MNH.0000000000000256","volume":"25","author":"OC Logue","year":"2016","unstructured":"Logue OC, McGowan JWD, George EM, Bidwell GL (2016) Therapeutic angiogenesis by vascular endothelial growth factor supplementation for treatment of renal disease. Curr Opin Nephrol Hypertens 25:404\u2013409","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"3990_CR28","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1046\/j.1523-1755.2001.00935.x","volume":"60","author":"S-I Suga","year":"2001","unstructured":"Suga S-I, Kim Y-G, Joly A, Puchacz E, Kang D-H, Jefferson JA et al (2001) Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. Kidney Int 60:1297\u20131308","journal-title":"Kidney Int"},{"key":"3990_CR29","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1681\/ASN.V1271448","volume":"12","author":"D-H Kang","year":"2001","unstructured":"Kang D-H, Hughes J, Mazzali M, Schreiner GF, Johnson RJ (2001) Impaired angiogenesis in the remnant kidney model. J Am Soc Nephrol 12:1448\u20131457","journal-title":"J Am Soc Nephrol"},{"key":"3990_CR30","doi-asserted-by":"publisher","first-page":"F727","DOI":"10.1152\/ajprenal.2001.280.4.F727","volume":"280","author":"D-H Kang","year":"2001","unstructured":"Kang D-H, Kim Y-G, Andoh TF, Gordon KL, Suga S-I, Mazzali M et al (2001) Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor. Am J Physiol-Renal Physiol 280:F727\u2013F736","journal-title":"Am J Physiol-Renal Physiol"},{"issue":"10","key":"3990_CR31","doi-asserted-by":"publisher","first-page":"F1342","DOI":"10.1152\/ajprenal.00674.2011","volume":"302","author":"AR Chade","year":"2012","unstructured":"Chade AR, Kelsen S (2012) Reversal of renal dysfunction by targeted administration of VEGF into thestenotic kidney: a novel potential therapeutic approach. Am J Physiol-Renal physiol 302(10):F1342\u2013F1350.\u00a0https:\/\/doi.org\/10.1152\/ajprenal.00674.2011","journal-title":"Am J Physiol-Renal physiol"},{"key":"3990_CR32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1146\/annurev.med.58.061705.145635","volume":"58","author":"N Ferrara","year":"2007","unstructured":"Ferrara N, Mass RD, Campa C, Kim R (2007) Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 58:491\u2013504","journal-title":"Annu Rev Med"},{"key":"3990_CR33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2174\/138161206775201910","volume":"12","author":"AR Cardones","year":"2006","unstructured":"Cardones AR, Banez LL (2006) VEGF inhibitors in cancer therapy. Curr Pharm Des 12:387\u2013394","journal-title":"Curr Pharm Des"},{"key":"3990_CR34","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminoncol.2006.08.002","volume":"33","author":"LM Ellis","year":"2006","unstructured":"Ellis LM (2006) Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol 33:S1-7","journal-title":"Semin Oncol"},{"key":"3990_CR35","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548","journal-title":"Ophthalmology"},{"key":"3990_CR36","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","volume":"32","author":"S Fogli","year":"2018","unstructured":"Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R (2018) Clinical pharmacology of intravitreal anti-VEGF drugs. Eye (Lond) 32:1010\u20131020","journal-title":"Eye (Lond)"},{"key":"3990_CR37","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.preteyeres.2003.08.001","volume":"22","author":"A Das","year":"2003","unstructured":"Das A, McGuire PG (2003) Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 22:721\u2013748","journal-title":"Prog Retin Eye Res"},{"key":"3990_CR38","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.ajo.2004.04.058","volume":"138","author":"DS Friedman","year":"2004","unstructured":"Friedman DS, Wilson MR, Liebmann JM, Fechtner RD, Weinreb RN (2004) An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol 138:S19-31","journal-title":"Am J Ophthalmol"},{"key":"3990_CR39","first-page":"2803","volume":"15","author":"H Kim","year":"2009","unstructured":"Kim H, Robinson SB, Csaky KG (2009) FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 15:2803\u20132812","journal-title":"Mol Vis"},{"key":"#cr-split#-3990_CR40.1","doi-asserted-by":"crossref","unstructured":"Powner MB, McKenzie JAG, Christianson GJ, Roopenian DC, Fruttiger M (2014) Expression of neonatal Fc receptor in the eye [Internet]. Investigative ophthalmology","DOI":"10.1167\/iovs.13-12574"},{"key":"#cr-split#-3990_CR40.2","unstructured":"visual science. UCL Institute of Ophthalmology, University College London, London, United Kingdom. p. 1607-15. Available from: http:\/\/europepmc.org\/abstract\/MED\/24550358 Accessed 24 Nov 2023."},{"key":"3990_CR41","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179\u20132182","journal-title":"Ophthalmology"},{"key":"3990_CR42","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","volume":"98","author":"RL Avery","year":"2014","unstructured":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R et al (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98:1636\u20131641","journal-title":"Br J Ophthalmol"},{"key":"3990_CR43","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R et al (2017) Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab and ranibizumab. Retina 37:1847\u20131858","journal-title":"Retina"},{"key":"3990_CR44","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/aos.12604","volume":"93","author":"C Zehetner","year":"2015","unstructured":"Zehetner C, Kralinger MT, Modi YS, Waltl I, Ulmer H, Kirchmair R et al (2015) Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Ophthalmol 93:e154\u2013e159","journal-title":"Acta Ophthalmol"},{"key":"3990_CR45","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3341\/jkos.2016.57.3.429","volume":"57","author":"MH Yoon","year":"2016","unstructured":"Yoon MH, Kim YJ, Lee SY, Lee KW, Chin HS (2016) Effects of intravitreal injection of bevacizumab or ranibizumab on systemic circulation. jkos 57:429\u2013437. https:\/\/doi.org\/10.3341\/jkos.2016.57.3.429","journal-title":"jkos"},{"key":"3990_CR46","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.oret.2017.05.015","volume":"2","author":"CA Rogers","year":"2018","unstructured":"Rogers CA, Scott LJ, Reeves BC, Downes S, Lotery AJ, Dick AD et al (2018) Serum vascular endothelial growth factor levels in the IVAN trial; relationships with drug, dosing, and systemic serious adverse events. Ophthalmol Retina 2:118\u2013127","journal-title":"Ophthalmol Retina"},{"key":"3990_CR47","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1097\/IAE.0000000000002004","volume":"38","author":"T Hirano","year":"2018","unstructured":"Hirano T, Toriyama Y, Iesato Y, Imai A, Murata T (2018) Changes in plasma vascular endothelial growth factor level after intravitreal injection of bevacizumab, aflibercept, or ranibizumab for diabetic macular edema. Retina 38:1801\u20131808","journal-title":"Retina"},{"key":"3990_CR48","doi-asserted-by":"publisher","first-page":"e113701","DOI":"10.1371\/journal.pone.0113701","volume":"9","author":"A Tschulakow","year":"2014","unstructured":"Tschulakow A, Christner S, Julien S, Ludinsky M, van der Giet M, Schraermeyer U (2014) Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys. PLoS ONE 9:e113701. https:\/\/doi.org\/10.1371\/journal.pone.0113701","journal-title":"PLoS ONE"},{"key":"3990_CR49","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1097\/IAE.0b013e3181b21056","volume":"29","author":"K Lee","year":"2009","unstructured":"Lee K, Yang H, Lim H, Lew HM (2009) A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection. Retina 29:1409\u20131417","journal-title":"Retina"},{"key":"3990_CR50","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/eye.2008.360","volume":"23","author":"R Rasier","year":"2009","unstructured":"Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H (2009) The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye (Lond) 23:1714\u20131718","journal-title":"Eye (Lond)"},{"key":"3990_CR51","doi-asserted-by":"publisher","DOI":"10.31661\/gmj.v7i0.1299","volume":"7","author":"S Bagheri","year":"2018","unstructured":"Bagheri S, Dormanesh B, Afarid M, Sagheb MM (2018) Proteinuria and renal dysfunction after intravitreal injection of bevacizumab in patients with diabetic nephropathy: a prospective observational study. Galen Med J 7:e1299","journal-title":"Galen Med J"},{"key":"3990_CR52","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.oret.2019.01.019","volume":"3","author":"AR Shah","year":"2019","unstructured":"Shah AR, Van Horn AN, Verchinina L, Wichorek M, Su L, Markel D et al (2019) Blood pressure is associated with receiving intravitreal anti-vascular endothelial growth factor treatment in patients with diabetes. Ophthalmol Retina 3:410\u2013416","journal-title":"Ophthalmol Retina"},{"key":"3990_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa142.P0590","author":"M Jalalonmuhali","year":"2020","unstructured":"Jalalonmuhali M, TengkuKamalden TAF, Ismail Ain S, Yong SY, Teo WT, Lim SK (2020) P0590ADVERSE renal outcome following administration of intravitreal anti-vascular endothelial growth factor inhibitors in a single tertiary centre in Malaysia. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaa142.P0590","journal-title":"Nephrol Dial Transplant"},{"key":"3990_CR54","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1167\/iovs.17-22853","volume":"59","author":"AR Glassman","year":"2018","unstructured":"Glassman AR, Liu D, Jampol LM, Sun JK (2018) Changes in blood pressure and urine albumin-creatinine ratio in a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. Invest Ophthalmol Vis Sci 59:1199\u20131205","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3990_CR55","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/jdi.12771","volume":"9","author":"Y Kameda","year":"2018","unstructured":"Kameda Y, Babazono T, Uchigata Y, Kitano S (2018) Renal function after intravitreal administration of vascular endothelial growth factor inhibitors in patients with diabetes and chronic kidney disease. J Diabetes Investig 9:937\u2013939","journal-title":"J Diabetes Investig"},{"key":"3990_CR56","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/s12882-019-1650-1","volume":"20","author":"RA O\u2019Neill","year":"2019","unstructured":"O\u2019Neill RA, Gallagher P, Douglas T, Little J-A, Maxwell AP, Silvestri G et al (2019) Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease. BMC Nephrol 20:478. https:\/\/doi.org\/10.1186\/s12882-019-1650-1","journal-title":"BMC Nephrol"},{"key":"3990_CR57","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.ophtha.2007.05.062","volume":"114","author":"IU Scott","year":"2007","unstructured":"Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ et al (2007) A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114:1860\u20131867","journal-title":"Ophthalmology"},{"key":"3990_CR58","doi-asserted-by":"crossref","first-page":"2050313X2090703","DOI":"10.1177\/2050313X20907033","volume":"8","author":"RM Hanna","year":"2020","unstructured":"Hanna RM, Abdelnour L, Hasnain H, Selamet U, Kurtz I (2020) Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab. SAGE Open Med Case Rep 8:2050313X20907033","journal-title":"SAGE Open Med Case Rep"},{"key":"3990_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.579603","volume":"7","author":"RM Hanna","year":"2020","unstructured":"Hanna RM, Tran N-T, Patel SS, Hou J, Jhaveri KD, Parikh R et al (2020) Thrombotic microangiopathy and acute kidney injury induced after intravitreal injection of vascular endothelial growth factor inhibitors VEGF blockade-related TMA after intravitreal use. Front Med (Lausanne) 7:579603","journal-title":"Front Med (Lausanne)"},{"key":"3990_CR60","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581\u2013611","journal-title":"Endocr Rev"},{"key":"3990_CR61","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/CAD.0b013e3283161012","volume":"20","author":"V Launay-Vacher","year":"2009","unstructured":"Launay-Vacher V, Deray G (2009) Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 20:81\u201382","journal-title":"Anticancer Drugs"},{"key":"3990_CR62","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1053\/j.ajkd.2006.11.024","volume":"49","author":"BA George","year":"2007","unstructured":"George BA, Zhou XJ, Toto R (2007) Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 49:e23\u2013e29","journal-title":"Am J Kidney Dis"},{"key":"3990_CR63","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1016\/j.humpath.2014.05.015","volume":"45","author":"J Usui","year":"2014","unstructured":"Usui J, Glezerman IG, Salvatore SP, Chandran CB, Flombaum CD, Seshan SV (2014) Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Hum Pathol 45:1918\u20131927","journal-title":"Hum Pathol"},{"key":"3990_CR64","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J et al (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129\u20131136","journal-title":"N Engl J Med"},{"key":"3990_CR65","first-page":"8675","volume":"7","author":"N Zhao","year":"2014","unstructured":"Zhao N, Xu Q, Wang M, Fei X, Pan Y, Chen X et al (2014) Mechanism of kidney injury caused by bevacizumab in rats. Int J Clin Exp Pathol 7:8675\u20138683","journal-title":"Int J Clin Exp Pathol"},{"key":"3990_CR66","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","volume":"30","author":"CC Estrada","year":"2019","unstructured":"Estrada CC, Maldonado A, Mallipattu SK (2019) Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol 30:187\u2013200","journal-title":"J Am Soc Nephrol"},{"key":"3990_CR67","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1097\/HJH.0000000000000326","volume":"32","author":"O Grisk","year":"2014","unstructured":"Grisk O, Koenen A, Meissner T, Donner A, Braun D, Steinbach A et al (2014) Rho kinase inhibition mitigates sunitinib-induced rise in arterial pressure and renal vascular resistance but not increased renal sodium reabsorption. J Hypertens 32:2199\u20132210","journal-title":"J Hypertens"},{"key":"3990_CR68","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1097\/HJH.0000000000001650","volume":"36","author":"J Witte","year":"2018","unstructured":"Witte J, Lampe J, Koenen A, Urbaneck I, Steinbach A, Rettig R et al (2018) The role of distal tubule and collecting duct sodium reabsorption in sunitinib-induced hypertension. J Hypertens 36:892\u2013903","journal-title":"J Hypertens"},{"key":"3990_CR69","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","volume":"49","author":"X Zhu","year":"2007","unstructured":"Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49:186\u2013193","journal-title":"Am J Kidney Dis"},{"key":"3990_CR70","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/ajh.2010.25","volume":"23","author":"V Ranpura","year":"2010","unstructured":"Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23:460\u2013468","journal-title":"Am J Hypertens"},{"key":"3990_CR71","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1093\/annonc\/mdv136","volume":"26","author":"V Launay-Vacher","year":"2015","unstructured":"Launay-Vacher V, Aapro M, De Castro G, Cohen E, Deray G, Dooley M et al (2015) Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Ann Oncol 26:1677\u20131684","journal-title":"Ann Oncol"},{"key":"3990_CR72","doi-asserted-by":"publisher","first-page":"22332","DOI":"10.18632\/oncotarget.24900","volume":"9","author":"G Roviello","year":"2018","unstructured":"Roviello G, Corona SP, Multari AG, Paganini G, Chiriac\u00f2 G, Conca R et al (2018) Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer. Oncotarget 9:22332\u201322339","journal-title":"Oncotarget"},{"key":"3990_CR73","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/jch.12273","volume":"16","author":"Y Li","year":"2014","unstructured":"Li Y, Li S, Zhu Y, Liang X, Meng H, Chen J et al (2014) Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 16:177\u2013185","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"3990_CR74","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1634\/theoncologist.2012-0339","volume":"18","author":"HI Hurwitz","year":"2013","unstructured":"Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA et al (2013) Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 18:273\u2013280","journal-title":"Oncologist"},{"key":"3990_CR75","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/jnci\/djq091","volume":"102","author":"ML Maitland","year":"2010","unstructured":"Maitland ML, Bakris GL, Black HR, Chen HX, Durand J-B, Elliott WJ et al (2010) Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102:596\u2013604","journal-title":"J Natl Cancer Inst"},{"key":"3990_CR76","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.amjhyper.2005.04.023","volume":"18","author":"AJ Siddiqui","year":"2005","unstructured":"Siddiqui AJ, Mansson-Broberg A, Gustafsson T, Grinnemo KH, Dellgren G, Hao X et al (2005) Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart. Am J Hypertens 18:1347\u20131352","journal-title":"Am J Hypertens"},{"key":"3990_CR77","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3892\/br.2022.1529","volume":"16","author":"N Chebotareva","year":"2022","unstructured":"Chebotareva N, Grechukhina K, Mcdonnell V, Zhukova L, Krasnova T (2022) Early biomarkers of nephrotoxicity associated with the use of anti-VEGF drugs. Biomed Rep 16:46","journal-title":"Biomed Rep"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-03990-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-024-03990-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-03990-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T03:38:03Z","timestamp":1721792283000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-024-03990-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":78,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3990"],"URL":"https:\/\/doi.org\/10.1007\/s11255-024-03990-1","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"11 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no competing interests. No financial help was taken for preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}